metastatic colorectal cancer
Conditions
Interventions
Case series:bevacizumab combined with S-1 and raltitrexed
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Pathologic diagnosis confirming, metastatic colorectal adenocarcinoma. 2) Aged at least 18 years old male and female; 3) Expected survival more than 12 weeks; 4) ECOG PS score was 0-2; 5) Failure of 5-fluorouracil (or capecitabine), oxaliplatin and irinotecan; 6) no use of Raltitrexed or S-1 in the treatment of metastatic colorectal cancer; 7) Bevacizumab has never been used or used only once in the previous chemotherapy regimen before enrollment. 8) Patients were at least 2 weeks after the last chemotherapy or 4 weeks after the end of radiotherapy, and the lesions were observed in the non-radiotherapy target area in this study 9) According to the RECIST1.1, at least one measurable lesion:spiral CT examination, its maximum diameter must be more than 1cm; ordinary CT or MRI, and its maximum diameter must be more than 2cm; 10) adequate bone-marrow, liver, and renal function: Hemoglobin more than 90g/L; Platelets (PLT) more than 75 x 10^9/L; White blood cell (WBC) more than 3 x 109/L; neutrophils (ANC) more than 1.5 x 10^9/L; Total bilirubin (TBI) less than 1.5 x normal upper limit (UNL); Serum creatinine (Cr) less than 1.5 x upper limit of normal value. Glutamic pyruvic transaminase (ALT) and aspartate aminotransferase (AST) less than 2.5 x UNL(if liver metastases less than 5 x UNL); 11) Patients volunteered to participate in this study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Severe hepatorenal insufficiency or recent myocardial infarction (within 3 months); 2) With other malignancy history in 5 years (except for basal cell carcinoma of the skin and in situ cervical cancer); 3) With brain metastases or nervous system oppressors; 4) Serious uncontrolled internal diseases or acute infections (fever caused by infection over 38 degrees); 5) Serious internal and external diseases affect organ function; 6) Pregnant women or lactating women or those with fertility (men or women who are less than 1 years' menopause) are unwilling to take contraceptive measures; 7) With a history of chronic diarrhea or complete intestinal obstruction; 8) Underwent major surgery within the first 28 days of admission; 9) Take aspirin regularly (over 325mg/ days) or other non steroidal anti-inflammatory drugs; 10) Patients who had bleeding tendency, coagulopathy or need full dose anticoagulation therapy; 11) Known to be allergic to bevacizumab or Raltitrexed or S-1 and its components; 12) The researchers judged patients who were not suitable for this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR; | — |
Countries
China
Contacts
Public ContactHong-Feng Gou
Department of Abdominal Oncology,West China Hospital of Sichuan University
Outcome results
None listed